Michael Liebowitz
Psychiatry · New York, NYNPI 1265578629
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $11,120 of the $13,479 with a category attached, or 82.5%. Sunovion Pharmaceuticals Inc. accounts for 84.4% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2022 at $11,195 and has fallen 98.9% since, to $124 in 2025. Among psychiatry clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 125 payments — averaging $107.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$11K
- AbbVie$933
- Lundbeck LLC$355
- Otsuka America Pharmaceutical, Inc.$165
- Biogen$156
- Takeda Pharmaceuticals U.S.A., Inc.$139
- plus $361 from 8 others
Across 384 payments — averaging $18,685 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$2.6M
- Otsuka Pharmaceutical Development & Commercialization, Inc.$2.4M
- AbbVie$933K
- Acadia Pharmaceuticals Inc$547K
- Supernus Pharmaceuticals, Inc.$445K
- Sunovion Pharmaceuticals Inc.$118K
- plus $136K from 2 others
What the payments were for
- Consulting fees$11,12082%
- Speaking & faculty fees$630%
- Food & beverage$2,10616%
- Education$1911%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 16 | $11,371 |
| AbbVie(2 entities) | 49 | $933 |
| Lundbeck LLC | 21 | $355 |
| Otsuka America Pharmaceutical, Inc. | 9 | $165 |
| Biogen | 3 | $156 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $139 |
| Johnson & Johnson | 7 | $131 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $63 |
| Avanir Pharmaceuticals, Inc. | 3 | $50 |
| Shire North American Group Inc | 2 | $34 |
| Jazz Pharmaceuticals Inc. | 2 | $33 |
| Boehringer Ingelheim | 1 | $19 |
| Ironshore Pharmaceuticals Inc. | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
How this compares
$13,479 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 20 | $44,607 |
| RisperdalRisperidone | 22 | $7,873 |
| Clozapine | 130 | $5,746 |
| Nimodipine | 14 | $3,036 |
| Divalproex Sodium ErDivalproex Sodium | 44 | $2,237 |
| Olanzapine | 72 | $1,423 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 84 | $1,377 |
| Bupropion Hcl | 35 | $1,346 |
| Lurasidone Hcl | 27 | $1,329 |
| SynthroidLevothyroxine Sodium | 18 | $1,238 |
| Duloxetine Hcl | 91 | $1,231 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 65 | $838 |
| Divalproex Sodium | 69 | $786 |
| Clomipramine Hcl | 16 | $776 |
| Sertraline Hcl | 47 | $732 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonRisperdal | $131 | $7,87322 claims |
| AbbVieSynthroid | $933 | $1,23818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in New York
- Manish ZinzuvadiaNew York$1.3M
- Jianping ChenNew York$1.2M
- Ulla Kristina LaaksoNew York$890K
- Kerry SulkowiczNew York$435K
- Ralph AquilaNew York$143K
- Daniel KarlinNew York$101K
- David StraussNew York$95K
- Anissa Abi-DarghamNew York$94K
- Robin McGarryNew York$69K
- Nicole AllenNew York$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.